Ischemia-reperfusion injury Stroke Neuroprotection a b s t r a c t Serofendic acid is a low-molecular-weight compound extracted from fetal calf serum.
Introduction
Cerebral ischemia-reperfusion causes injury to brain tissues, including neurons, glial cells, and cerebral blood vessels, resulting in their dysfunction. Numerous studies have revealed the possible factors that cause cell damage and the therapeutic targets of cerebral ischemia-reperfusion injury. For instance, massive release of glutamate into the extracellular space, induction of oxidative stress, and generation of proinflammatory cytokines occur during or after ischemia. Suppression of these events attenuates ischemic insults (Lakhan et al., 2009; Mehta et al., 2007; Nakka et al., 2008;  0006 Park et al., 1988; Peters et al., 1998; Tuttolomondo et al., 2009 ). There are two regions in an ischemic brain: the ischemic core and the penumbra. In the ischemic core region, neurons and glial cells suffer severe injury characterized by necrosis and their function is irreversibly impaired during the acute phase of ischemia-reperfusion. In the penumbra region, cell insults are moderate and cell death due to apoptosis progresses for several days (Ueda and Fujita, 2004) . Research into agent intervention to save cells from cell death in the penumbra region is ongoing (Barone, 2009; Kaushal and Schlichter, 2008) . We previously found a neuroprotective substance, serofendic acid, in a lipophilic extract of fetal calf serum. Serofendic acid is 15-hydroxy-17-methylsulfinylatisan-19-oic acid and a sulfur-containing atisan-type diterpenoid (Kume et al., 2002) . It is a low-molecular-weight (mw 382) compound and exhibits potent protective effects on neurotoxicity induced by glutamate, NO, and oxidative stress without inhibiting glutamate receptors in cultured cortical, striatal, and spinal cord neurons (Kume et al., 2005 Osakada et al., 2004; Taguchi et al., 2003) . Moreover, in cardiac myocytes, serofendic acid suppresses cell death induced by oxidative stress (Akao et al., 2007; Takeda et al., 2006) . While the mechanism of protection remains unclear, it has been demonstrated that serofendic acid inhibits the generation of hydroxyl radicals and prevents mitochondrial membrane depolarization and caspase-3 activation Osakada et al., 2004; Taguchi et al., 2003) . We have previously reported the protective effect of serofendic acid on ischemiareperfusion injury induced by transient middle cerebral artery occlusion (tMCAo) in rats. Intracerebroventricular administration of serofendic acid reduced the infarct volume, particularly in the cortex, and improved neurological deficit scores (Nakamura et al., 2008) . However, we previously reported that serofendic acid had a very low brain-toplasma value (0.021), as passive transport of serofendic acid hardly occurs because of the existence of the carboxylic group (Terauchi et al., 2007) . Thus, there are no reports of the effect of peripheral administration of serofendic acid on cerebral ischemia-reperfusion injury. Whereas, serofendic acid enters into the brain in some degree in intravenous administration (Terauchi et al., 2007) and it protects against cerebral ischemia-reperfusion injury at low concentration in the brain
Three administrations
Vehicle Serofendic acid (10 mg/kg) 1 cm Nakamura et al., 2008) . Therefore, we investigated the effect of serofendic acid administrated intravenously on ischemiareperfusion injury induced by tMCAo in rats.
Results

2.1.
Intravenously administered serofendic acid reduces infarct volume and neurological deficit induced by transient middle cerebral artery occlusion (MCAo) in a dose-dependent manner
We examined the protective effect of multiple intravenous administration of serofendic acid because blood level of serofendic acid is immediately decreased (Terauchi et al., 2007) . As a multiple administration, we utilized three times administration of serofendic acid at 30 min before the onset of ischemia, just (within 5 min) after the onset of ischemia, and just (whithin 5 min) before reperfusion. Three times administration of serofendic acid (10 mg/kg) reduced infarct volume (Fig. 1) .
Next, we examined the dose-dependent effect of serofendic acid on infarct volume. Three times administration of serofendic acid (1-10 mg/kg) reduced infarct volume in a dose-dependent manner ( Fig. 2A) . We examined the functional recovery by three times administration of serofendic acid with the evaluation of neurological deficit scores. Serofendic acid (1-10 mg/kg) improved neurological deficit scores in a dose-dependent manner (Fig. 2B) . It is suggested that necrotic cell death occurs at ischemic core region and apoptotic cell death occurs at ischemic penumbra region (Ueda and Fujita, 2004) . So, we examined the infarct volume limitation effect of serofendic acid at ischemic core (striatum) and penumbra (cerebral cortex) region to suggest that serofendic acid protects from which type of cell death. Serofendic acid significantly reduced the infarct volume at cerebral cortex, but did not affect the infarct volume at striatum (Fig. 3 ).
2.2.
Intravenously administered serofendic acid does not effect regional cerebral blood flow Cerebral blood flow is a crucial factor for ischemic insults. Thus, we further examined the effect of serofendic acid on regional cerebral blood flow (rCBF) at just after ischemia, just before reperfusion, and just after reperfusion. Serofendic acid did not regulate rCBF at ischemic and reperfusion phase (Table 1) .
2.3.
Intravenously administered serofendic acid does not affect physiological parameters Several physiological parameters (pH, PaO 2 , PaCO 2 , and glucose content of arterial blood) influence the degree of cerebral damages induced ischemia-reperfusion. Thus, we investigated the effect of serofendic acid on physiological parameters 30 min after each of the three administrations. We found no effect of serofendic acid on any physiological parameters in the sham-operated and ischemia-reperfusion-operated groups (Table 2) .
2.4.
Single intravenous administration of serofendic acid does not reduce infarct volume and neurological deficit induced by transient middle cerebral artery occlusion Next, we administered a single dose of serofendic acid (30 mg/kg) at 30 min before ischemia, just after ischemia, or just before reperfusion in order to determine whether three administrations are necessary to achieve protective effects. No single administration of serofendic acid showed any protective effect on infarct volume or neurological deficit score (Fig. 4) .
Discussion
The major finding of this study is that serofendic acid, administered intravenously, has the protective effect on the injury induced by cerebral ischemia-reperfusion. We have previously reported that intracerebroventricular administration of serofendic acid protects against ischemic injury in tMCAo model rats (Nakamura et al., 2008) . However, it was not sufficient for considering about clinical application of serofendic acid because of the poor permeability into brain in case of peripheral administration. In the present study, we showed that intravenous administration of serofendic acid, when administrated three times, reduced infarct volume and improved neurological function without affecting rCBF or physiological parameters.
As shown in Fig. 3 , serofendic acid reduced the infarct volume in the cortex but not in striatum, similar to our previous results for intracerebroventricular administration (Nakamura et al., 2008) . We previously reported that serofendic acid inhibits caspase-3 activation in vitro and several reports showed that inhibition of caspases attenuates apoptosis in the penumbra in tMCAo models (Lei et al., 2004; Sung et al., 2007) . Thus, the inhibition of activation of caspases-3 is suggested to play a central role in the protective effect of serofendic acid in the cortex.
We previously reported that serofendic acid affords protection against reactive oxygen species (ROS)-induced oxidative injury (Osakada et al., 2004) . Many anti-oxidative substances have been shown to have protective effects against cerebral ischemia-reperfusion injury (Amemiya et al., 2005; Connell et al., 2011; Shih et al., 2005) . Taken together, we can assume that the anti-oxidative properties of serofendic acid contribute its protective effect against cerebral ischemia-reperfusion injury.
Based on our previous reports regarding the permeability of serofendic acid into the brain (Terauchi et al., 2007) , we estimated that the brain dose of serofendic acid in normal condition with intravenous treatment of 10 mg/kg was equivalent to 2.1 nmol. Our previous report showed that 10 nmol of serofendic acid with intracerebroventricular treatment was required to exhibit the protective effect on ischemic neuronal damage (Nakamura et al., 2008) . Thus, we predicted that serofendic acid may fail to protect the brain from ischemia-reperfusion injury when administered intravenously. Contrary to our expectations, intravenous administration of serofendic acid exerted protective effects on cerebral ischemia-reperfusion injury without affecting rCBF and physiological parameters. While serofendic acid has a relatively low ability to penetrate the blood brain barrier (BBB), it can be detected in the brain after intravenous administration (Terauchi et al., 2007) . We assume that its low concentration in the brain is able to exert a protective effect since a low dose (10-30 nmol) of intracerebroventricularly administered serofendic acid was effective on cerebral ischemia-reperfusion injury (Nakamura et al., 2008) . Thus, the small amount of serofendic acid that penetrates into the brain tissue may be sufficient to protect cells from ischemiareperfusion injury.
Since cerebral ischemia-reperfusion injury leads to the breakdown of BBB, molecules that cannot infiltrate the BBB in normal conditions may be able to do so more in case of cerebral ischemia-reperfusion injury (Haile et al., 2010; Michalski et al., 2010) . It is possible that serofendic acid Serofendic acid was administered intravenously 30 min before ischemia, just after ischemia, and just before reperfusion. There were no statistically significant differences at any time among the groups. F drug ¼ 1.67.
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 -1 0 5 may pass through the injured BBB more easily than under normal conditions. Further studies are needed to determine whether BBB disruption is required for a sufficient amount of serofendic acid to pass through. In the present study, three administrations of serofendic acid exerted protective effects on cerebral ischemiareperfusion injury, whereas single administration did not protect from ischemia-reperfusion injury. In our previous study, serofendic acid exhibited a high clearance value when administered intravenously (T 1/2 : 0.65 h) (Terauchi et al., 2007) . Thus, the protective effects from three administrations of serofendic acid are not because of the total dose (30 mg/kg) but because of persistent blood concentrations. We showed that protective effect of serofendic acid administrated intravenously requires pretreatment before ischemia, whereas serofendic acid intracerebroventricularly administered at 30 min after the onset of ischemia protected brain from ischemia-reperfusion injury (Nakamura et al., 2008) . This difference may have occurred owing to the poor ability of serofendic acid to penetrate BBB or be retained in the brain tissue. Regulation of pharmacokinetics of serofendic acid may enable serofendic acid administered intravenously after the onset of ischemia to exert protective effect on ischemiareperfusion injury.
In conclusion, our study shows that intravenous administration of serofendic acid has protective effects on cerebral ischemia-reperfusion injury induced by transient middle cerebral artery occlusion in rats. Our results offer the important findings for development of therapeutic agents of cerebral ischemia-reperfusion injury.
4.
Experimental procedure
Animals
Experiments were performed using 10-week-old male SpragueDawley rats weighing 300-330 g, which were purchased from Nihon SLC (Shizuoka, Japan). The animals were treated in accordance with the guidelines of the Kyoto University Animal Experimentation Committee and the Japanese Pharmacological Society.
Surgical procedure and drug administration
The middle cerebral artery was occluded for 90 min and then reperfused for 48 h using the intraluminal suture technique, which was modified as described previously (Nagasawa and Kogure, 1989) . Briefly, rats were anesthetized with halothane (3.5% for induction, 1% for maintenance, Takeda Pharmaceutical, Co., Ltd., Osaka, Japan) during surgery. After median incision of the neck skin, the left common and external carotid arteries were carefully exposed and ligated. A 19-mm length of silicon-coated 4-0 nylon surgical thread was transiently inserted into the left internal carotid artery for 90 min to occlude the left middle cerebral artery at its origin. While the Serofendic acid was administered intravenously 30 min before ischemia, just after ischemia, and just before reperfusion. There were no statistically significant differences in any parameters at any time among the groups.
b r a i n r e s e a r c h 1 5 3 2 ( 2 0 1 3 ) 9 9 -1 0 5 animals were anesthetized, rectal temperatures were maintained at 37.070.5 1C. Sham-operated animals underwent the same procedure except for a transient occlusion. Animals were randomly divided into serofendic acid-and vehicle-treated groups. Serofendic acid was dissolved in 1 N NaOH and diluted with 50 mM PBS. Rats were intravenously administered serofendic acid or vehicle either once or three times at 30 min before the onset of ischemia, just (within 5 min) after the onset of ischemia, and just (within 5 min) before reperfusion. Serofendic acid was synthesized as described previously (Terauchi et al., 2007) and supplied by Eisai Co., Ltd. (Tsukuba, Japan).
Evaluation of infarct volume by TTC staining
Infarct volume was evaluated as described previously (Zhao et al., 2005) . Briefly, rats were anesthetized with pentobarbital (80 mg/kg, i.p.) and perfused with cold PBS through the left ventricle. The brain was quickly removed and sliced into eight 2-mm thick coronal sections using a brain slicer (Brain science Idea, Co., Ltd., Osaka, Japan). The slices were immersed in a saline solution containing 2% 2,3,5-triphenyltetrazolium chloride (TTC, Nakalai Tesque, Kyoto, Japan) and fixed by 10% neutral formalin isotonic fluid. The sections were quantified using Image J software. Total infarct volume was determined by summing the infarct area of the eight sections. The infarct volume in the cortex or the striatum was determined by summing the sections numbered 3, 4, and 5 or 3 and 4, respectively. Results were calculated as a percentage of the ipsilateral to the contralateral hemispheric volume.
Assessment of neurological deficit scores
Neurological symptoms after 48 h of reperfusion were assessed using neurological deficit scores (grade 0-4), which were modified as described previously (Murakami et al., 1998) . Rats were suspended by the tail, and forelimb flexion and body twisting were evaluated as 0 (no observable neurological deficit), 1 (failed to extend right forepaw), 2 (circled to the right), 3 (failed to move the right forepaw), or 4 (could not walk spontaneously).
Measurement of regional blood flow
Regional cerebral blood flow in the left middle cerebral artery territory (7 mm lateral and 1 mm posterior to the bregma) was measured at each time point (before and after the onset of ischemia and at reperfusion) using Laser-Doppler flowmetry FLO-N1 (Omegawave Inc., Tokyo, Japan) as described previously (Amemiya et al., 2005) .
Measurement of physiological parameters
Blood gases, pH, PaO 2 , PaCO 2 , and glucose content were measured at 15 min before the first administration and 30 min after each administration using CG8 þ cartridges in a portable blood analyzer (i-STAT 300F, Fuso Pharmaceutical Industries, Ltd., Osaka, Japan).
Statistical analyses
Data are expressed as means7S.E.M. Statistical analyses were performed using GraphPad Instat (GraphPad Software, San Diego, USA). The dose-dependent effects of three administrations of serofendic acid on infarct volume in the cortex or the striatum were analyzed using one-way analysis of variance followed by Dunnet's two-tailed test. Kruskal-Wallis test was used for neurological deficit scores. Regional cerebral blood flow and physiological parameters were analyzed using two-way analysis of variance. Statistical significance was defined as a probability value of less than 5%. 
